Early neurotransmitters changes in prodromal frontotemporal dementia: A GENFI study
Enrico Premi,Marta Pengo,Irene Mattioli,Valentina Cantoni,Juergen Dukart,Roberto Gasparotti,Emanuele Buratti,Alessandro Padovani,Martina Bocchetta,Emily G Todd,Arabella Bouzigues,David M Cash,Rhian S Convery,Lucy L Russell,Phoebe Foster,David L Thomas,John C van Swieten,Lize C Jiskoot,Harro Seelaar,Daniela Galimberti,Raquel Sanchez-Valle,Robert Laforce Jr,Fermin Moreno,Matthis Synofzik,Caroline Graff,Mario Masellis,Maria Carmela Tartaglia,James B Rowe,Kamen A Tsvetanov,Rik Vandenberghe,Elizabeth Finger,Pietro Tiraboschi,Alexandre de Mendonça,Isabel Santana,Chris R Butler,Simon Ducharme,Alexander Gerhard,Johannes Levin,Markus Otto,Sandro Sorbi,Isabelle Le Ber,Florence Pasquier,Jonathan D Rohrer,Barbara Borroni,Genetic Frontotemporal dementia Initiative (GENFI),Aitana Sogorb Esteve,Carolin Heller,Caroline V Greaves,Henrik Zetterberg,Imogen J Swift,Kiran Samra,Rachelle Shafei,Carolyn Timberlake,Thomas Cope,Timothy Rittman,Andrea Arighi,Chiara Fenoglio,Elio Scarpini,Giorgio Fumagalli,Vittoria Borracci,Giacomina Rossi,Giorgio Giaccone,Giuseppe Di Fede,Paola Caroppo,Sara Prioni,Veronica Redaelli,David Tang-Wai,Ekaterina Rogaeva,Miguel Castelo-Branco,Morris Freedman,Ron Keren,Sandra Black,Sara Mitchell,Christen Shoesmith,Robart Bartha,Rosa Rademakers,Jackie Poos,Janne M Papma,Lucia Giannini,Rick van Minkelen,Yolande Pijnenburg,Benedetta Nacmias,Camilla Ferrari,Cristina Polito,Gemma Lombardi,Valentina Bessi,Michele Veldsman,Christin Andersson,Hakan Thonberg,Linn Öijerstedt,Vesna Jelic,Paul Thompson,Tobias Langheinrich,Albert Lladó,Anna Antonell,Jaume Olives,Mircea Balasa,Nuria Bargalló,Sergi Borrego-Ecija,Ana Verdelho,Carolina Maruta,Catarina B Ferreira,Gabriel Miltenberger,Frederico Simões do Couto,Alazne Gabilondo,Ana Gorostidi,Jorge Villanua,Marta Cañada,Mikel Tainta,Miren Zulaica,Myriam Barandiaran,Patricia Alves,Benjamin Bender,Carlo Wilke,Lisa Graf,Annick Vogels,Mathieu Vandenbulcke,Philip Van Damme,Rose Bruffaerts,Koen Poesen,Pedro Rosa-Neto,Serge Gauthier,Agnès Camuzat,Alexis Brice,Anne Bertrand,Aurélie Funkiewiez,Daisy Rinaldi,Dario Saracino,Olivier Colliot,Sabrina Sayah,Catharina Prix,Elisabeth Wlasich,Olivia Wagemann,Sandra Loosli,Sonja Schönecker,Tobias Hoegen,Jolina Lombardi,Sarah Anderl-Straub,Adeline Rollin,Gregory Kuchcinski,Maxime Bertoux,Thibaud Lebouvier,Vincent Deramecourt,Beatriz Santiago,Diana Duro,Maria João Leitão,Maria Rosario Almeida,Miguel Tábuas-Pereira,Sónia Afonso
DOI: https://doi.org/10.1016/j.nbd.2023.106068
Abstract:Background: Neurotransmitters deficits in Frontotemporal Dementia (FTD) are still poorly understood. Better knowledge of neurotransmitters impairment, especially in prodromal disease stages, might tailor symptomatic treatment approaches. Methods: In the present study, we applied JuSpace toolbox, which allowed for cross-modal correlation of Magnetic Resonance Imaging (MRI)-based measures with nuclear imaging derived estimates covering various neurotransmitter systems including dopaminergic, serotonergic, noradrenergic, GABAergic and glutamatergic neurotransmission. We included 392 mutation carriers (157 GRN, 164 C9orf72, 71 MAPT), together with 276 non-carrier cognitively healthy controls (HC). We tested if the spatial patterns of grey matter volume (GMV) alterations in mutation carriers (relative to HC) are correlated with specific neurotransmitter systems in prodromal (CDR® plus NACC FTLD = 0.5) and in symptomatic (CDR® plus NACC FTLD≥1) FTD. Results: In prodromal stages of C9orf72 disease, voxel-based brain changes were significantly associated with spatial distribution of dopamine and acetylcholine pathways; in prodromal MAPT disease with dopamine and serotonin pathways, while in prodromal GRN disease no significant findings were reported (p < 0.05, Family Wise Error corrected). In symptomatic FTD, a widespread involvement of dopamine, serotonin, glutamate and acetylcholine pathways across all genetic subtypes was found. Social cognition scores, loss of empathy and poor response to emotional cues were found to correlate with the strength of GMV colocalization of dopamine and serotonin pathways (all p < 0.01). Conclusions: This study, indirectly assessing neurotransmitter deficits in monogenic FTD, provides novel insight into disease mechanisms and might suggest potential therapeutic targets to counteract disease-related symptoms.